title: Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine.
abstract: 1. To assess the contribution of tubular secretion to the renal excretion of pyridostigmine, and its modification by other cationic drugs, six volunteers were given single oral doses of 60-mg pyridostigmine bromide with and without co-administration of ranitidine or pirenzepine. Renal clearances were determined by h.p.l.c. analysis of pyridostigmine and enzymic measurement of endogenous creatinine in plasma and urine. 2. In patients with myasthenia receiving continuous pyridostigmine therapy, renal clearance values were obtained in the same manner with and without ranitidine (10 patients) or pirenzepine (nine patients) co-medication. 3. Pyridostigmine was not bound to plasma proteins. Its renal clearance averaged 6.65 ml/min per kg (350% of the creatinine clearance) in all subjects, 74% being due to net tubular secretion. 4. Mean values for pyridostigmine renal clearance and for clearance by secretion were decreased in the presence of pirenzepine, but plasma concentrations were not affected significantly. Ranitidine caused a small non-significant decrease of the pyridostigmine clearance in patients. 5. Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0.23 h-1) when administered orally as a non-retarded preparation. 6. The renal clearance of creatinine was slightly increased by pyridostigmine in volunteers and slightly decreased by pirenzepine in the total group of subjects.
authors.affiliation: Institute of Toxicology, University of Tübingen, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Eiermann
authors.forename: N
authors.initials: N
authors.lastname: Sommer
authors.forename: D
authors.initials: D
authors.lastname: Winne
authors.forename: F
authors.initials: F
authors.lastname: Schumm
authors.forename: U
authors.initials: U
authors.lastname: Maier
authors.forename: U
authors.initials: U
authors.lastname: Breyer-Pfaff
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004347:Drug Interactions; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007678:Kidney Glomerulus / Q000187:drug effects / Q000378:metabolism*; D007684:Kidney Tubules / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000378:metabolism*; D010890:Pirenzepine / Q000494:pharmacology*; D011729:Pyridostigmine Bromide / Q000097:blood / Q000493:pharmacokinetics*; D011899:Ranitidine / Q000494:pharmacology*
chemical_list: D010890:Pirenzepine; D011899:Ranitidine; D011729:Pyridostigmine Bromide